Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
+0.94 (0.73%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 128.43 - 132.00
52 week 52.35 - 140.00
Open 130.20
Vol / Avg. 475,192.00/752,059.00
Mkt cap 10.86B
P/E     -
Div/yield     -
EPS -2.05
Shares 84.28M
Beta 1.84
Inst. own 78%
Aug 20, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: Patisiran and Revusiran for the treatment of Transthyretin (TTR)-Mediated Amyloidosis - 9:00AM EDT - Add to calendar
Aug 14, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AAT for the treatment of AAT Deficiency-associated liver disease - 2:00PM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 28, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection
Jul 23, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-CC5 for the treatment of Complement-Mediated Diseases
Jul 22, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AT3 for the treatment of Hemophilia and Rare Bleeding Disorders - Webcast
Jun 24, 2015
Alnylam Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 23, 2015
Alnylam Pharmaceuticals Inc to Discuss ALN-AT3 Phase 1 Clinical Data - Webcast
Jun 12, 2015
Alnylam Pharmaceuticals Inc Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases Corporate Call
Jun 10, 2015
Alnylam Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -273.92% -712.79%
Operating margin -281.72% -800.97%
EBITD margin - -777.39%
Return on average assets -15.04% -48.05%
Return on average equity -16.74% -59.74%
Employees 256 -
CDP Score - -


300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
David-Alexandre Gros Senior Vice President, Chief Business Officer
Age: 42
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 40
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 56
Bio & Compensation  - Reuters
Amy W. Schulman Director
Age: 54
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters